Online inquiry

IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5392MR)

This product GTTS-WQ5392MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD2 gene. The antibody can be applied in Psoriasis, severe chronic plaque research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001328609.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 914
UniProt ID P06729
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5392MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11036MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ10512MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY3002813
GTTS-WQ3106MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ11157MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MDX-1333
GTTS-WQ14627MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ15417MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ9933MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KB-004
GTTS-WQ4158MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI-754091
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW